Last reviewed · How we verify
Phase I - Mirdametinib - Level 1
Phase I - Mirdametinib - Level 1 is a Small molecule drug developed by Centre Georges Francois Leclerc. It is currently in Phase 1 development.
At a glance
| Generic name | Phase I - Mirdametinib - Level 1 |
|---|---|
| Sponsor | Centre Georges Francois Leclerc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma (PHASE1, PHASE2)
- Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. (PHASE1, PHASE2)
- MEK and MET Inhibition in Colorectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phase I - Mirdametinib - Level 1 CI brief — competitive landscape report
- Phase I - Mirdametinib - Level 1 updates RSS · CI watch RSS
- Centre Georges Francois Leclerc portfolio CI
Frequently asked questions about Phase I - Mirdametinib - Level 1
What is Phase I - Mirdametinib - Level 1?
Phase I - Mirdametinib - Level 1 is a Small molecule drug developed by Centre Georges Francois Leclerc.
Who makes Phase I - Mirdametinib - Level 1?
Phase I - Mirdametinib - Level 1 is developed by Centre Georges Francois Leclerc (see full Centre Georges Francois Leclerc pipeline at /company/centre-georges-francois-leclerc).
What development phase is Phase I - Mirdametinib - Level 1 in?
Phase I - Mirdametinib - Level 1 is in Phase 1.